Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 17/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20831766 | 0.77 | SLC6A2 (0.50) | SLC6A4SLC6A3SLC6A2CYP2D6HTR2C | |
| SCHEMBL5631147 | 0.77 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2CYP2D6HTR2C | |
| SCHEMBL5631728 | 0.77 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2CYP2D6HTR2C | |
| SCHEMBL5631141 | 0.77 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2CYP2D6HTR2C | |
| SCHEMBL7149297 | 0.75 | SLC6A2 (0.69) | SLC6A4SLC6A3SLC6A2CYP2D6HTR2C | |
| SCHEMBL5631288 | 0.75 | SLC6A2 (0.47) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL5631291 | 0.75 | SLC6A2 (0.47) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL5632269 | 0.75 | SLC6A2 (0.47) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL20818753 | 0.74 | HRH3 (0.40) | — | |
| SCHEMBL5631566 | 0.74 | SLC6A2 (0.49) | SLC6A4SLC6A3SLC6A2CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| EP-3684364-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | SLC6A4 524/4885SLC6A3 777/4885SLC6A2 332/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | SLC6A4 524/4885SLC6A3 777/4885SLC6A2 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.